| 247.775 4.305 (1.77%) | 02-27 12:56 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 288.78 | 1-year : | 337.3 |
| Resists | First : | 247.25 | Second : | 288.78 |
| Pivot price | 242.8  |
|||
| Supports | First : | 229.07 |
Second : | 217.83 |
| MAs | MA(5) : | 244.64 |
MA(20) : | 239.74 |
| MA(100) : | 208.96 |
MA(250) : | 180 |
|
| MACD | MACD : | 6.6 |
Signal : | 7.3 |
| %K %D | K(14,3) : | 82.9 |
D(3) : | 87.8 |
| RSI | RSI(14): 66.4 |
|||
| 52-week | High : | 247.25 | Low : | 138.39 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ JNJ ] has closed below upper band by 44.3%. Bollinger Bands are 31.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 245.58 - 247.23 | 247.23 - 248.59 |
| Low: | 238.83 - 240.45 | 240.45 - 241.79 |
| Close: | 241.09 - 243.73 | 243.73 - 245.91 |
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Fri, 27 Feb 2026
How Kon Knueppel, Jalen Johnson affect Bucks' playoff hopes - Milwaukee Journal Sentinel
Fri, 27 Feb 2026
Editorial: Mayor Brandon Johnson is leaving his successors with a financial ash heap. It’s worse than we thought. - Chicago Tribune
Thu, 26 Feb 2026
Tessa Johnson injury update, star guard out for South Carolina vs Missouri - Greenville Online
Thu, 26 Feb 2026
Tez Johnson’s ex-fiancée alleges he cheated on her on their engagement day - New York Post
Thu, 26 Feb 2026
Bears coach Ben Johnson gets 'A' grade in leaked NFLPA survey - Chicago Sun-Times
Thu, 26 Feb 2026
JUST IN: Hillary Clinton Deposition Paused After Lauren Boebert Leaks Photo to Benny Johnson - Yahoo
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 2,410 (M) |
| Shares Float | 2,410 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 75.6 (%) |
| Shares Short | 19,560 (K) |
| Shares Short P.Month | 20,430 (K) |
| EPS | 11.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 33.86 |
| Profit Margin | 28.4 % |
| Operating Margin | 23.9 % |
| Return on Assets (ttm) | 8.6 % |
| Return on Equity (ttm) | 35 % |
| Qtrly Rev. Growth | 9.1 % |
| Gross Profit (p.s.) | 26.6 |
| Sales Per Share | 39.08 |
| EBITDA (p.s.) | 14.04 |
| Qtrly Earnings Growth | 48.5 % |
| Operating Cash Flow | 24,530 (M) |
| Levered Free Cash Flow | 16,630 (M) |
| PE Ratio | 22.07 |
| PEG Ratio | 0 |
| Price to Book value | 7.18 |
| Price to Sales | 6.22 |
| Price to Cash Flow | 23.92 |
| Dividend | 1.29 |
| Forward Dividend | 0 |
| Dividend Yield | 0.5% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|